Physician profile
Muhammad Khan
NPI 1427481472
$2,170.96
in general payments reported to CMS, 2019-2025
40 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2024: $424 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $164.17 | 2024-2025 | Tagrisso, Lynparza, Bevespi Aerosphere |
| Genentech USA, INC. | $136.61 | 2024-2025 | Polivy, Tecentriq |
| Pfizer INC. | $130.57 | 2024-2025 | |
| Abbvie INC. | $126.35 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $125.00 | 2021 | |
| Merck Sharp & Dohme LLC | $118.01 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Sobi, INC | $92.05 | 2025 | |
| Aveo Pharmaceuticals, INC. | $92.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $80.39 | 2024-2025 | |
| Tempus Ai, INC | $69.35 | 2024-2025 | Xt Cdx |
| Legend Biotech USA INC. | $60.09 | 2024-2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $60.02 | 2025 | Clonoseq |
| Array Biopharma INC | $58.04 | 2024-2025 | Mektovi, Braftovi, Xalkori |
| Glaxosmithkline, LLC. | $57.79 | 2025 | Ojjaara |
| Taiho Oncology, INC. | $56.65 | 2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $52.38 | 2024-2025 | Optune Lua (Novottf-200t) |
| Janssen Biotech, INC. | $51.75 | 2024-2025 | Talvey, Tecvayli, Darzalex |
| Incyte Corporation | $50.54 | 2025 | Jakafi |
| Alexion Pharmaceuticals, INC. | $48.97 | 2025 | Ultomiris |
| Evoke Pharma, INC. | $45.23 | 2021 | |
| Agios Pharmaceuticals, INC. | $38.29 | 2025 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $37.77 | 2025 | Reblozyl |
| Iovance Biotherapeutics, INC. | $31.24 | 2025 | Amtagvi |
| Genzyme Corporation | $29.62 | 2025 | |
| Blueprint Medicines Corporation | $27.80 | 2025 | Ayvakit |
| Caris Mpi, INC. | $25.90 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $25.22 | 2025 | Vyloy |
| Stemline Therapeutics INC. | $24.62 | 2024 | Orserdu |
| Abbott Laboratories | $24.58 | 2024 | 2nd Gen Centrimag Primary Console |
| Takeda Pharmaceuticals U.S.A., INC. | $24.08 | 2025 | Alunbrig |
| Jazz Pharmaceuticals INC. | $22.13 | 2025 | |
| Adc Therapeutics America, INC. | $21.63 | 2025 | |
| Pharmacosmos Therapeutics INC. | $21.57 | 2024 | Monoferric |
| Kite Pharma, INC. | $21.35 | 2025 | Yescarta |
| Pharmaand Gmbh | $21.14 | 2025 | Rubraca |
| Tolmar, INC. | $21.14 | 2025 | Eligard, Rubraca |
| Exelixis INC. | $20.50 | 2025 | Cabometyx |
| Scpharmaceuticals INC. | $20.50 | 2025 | |
| Celgene Corporation | $20.33 | 2024 | Pomalyst |
| Intercept Pharmaceuticals, INC. | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.